LAUSR

Studies of hyperthermic intraperitoneal chemotherapy (HIPEC) have used peritoneal dialysate as a carrier solution for chemotherapy, likely because its use within the peritoneum is familiar to clinicians. Peritoneal dialysate, however, contains dextrose to create an osmotic gradient during dialysis. Hyperglycemia in peritoneal dialysis patients is a known and expected phenomenon. More than half of clinicians who perform HIPEC use a dextrosecontaining carrier solution, but this detail is often omitted in reports, and no standard carrier solution exists. In this study, we questioned our practice of using peritoneal dialysate as a carrier solution for HIPEC and hypothesized that its use was associated with significant perioperative hyperglycemia. We thought this was important since perioperative hyperglycemia is associated with increased morbidity and morality in general surgery, and standardization of HIPEC delivery has been cited as a goal for the American Society of Peritoneal Surface Malignancies.